9-Alpha-substituted estratrienes as selectively active estrogens

摘要

The disclosure relates to 9-alpha-substituted estratrienes of general formula (I), wherein R3, R7, R7', R13, R16, R17 and R17' are as defined in the specification, and R9 represents a linear-chain or branched-chain, optionally partially or fully halogenated alkenyl radical comprising between 2 and 6 carbon atoms, or an ethinyl radical or a prop-1-inyl radical - as pharmaceutical active ingredients which have, in vitro, a higher affinity to estrogen receptor preparations of the rat prostate than to estrogen receptor preparation of the rat uterus, and, in vivo, preferably a preferential action on the ovary compared to the uterus. The disclosure also relates to the production of these 9-alpha-substituted estratrienes, to the therapeutic application thereof and to pharmaceutical forms of administration containing the novel compounds. The disclosure further relates to the use of said compounds for treating illnesses and states related to estrogen deficiency.